UNSPSC 51414002: Mindodilol

This classification denotes a vasodilating agent and antihypertensive agent with the molecular formula C23H28N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5VI1D4HYXC, chemically known as 1-piperidineethanol, alpha-((1h-indol-4-yloxy)methyl)-4-(phenoxymethyl)- but generally known as mindodilol, which bears US NIH Compound Identifier 68892. European Medicines Agency schedules Mindodilol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08976MIG.

UNSPSC 51414002 Mindodilol, a Commodity code, reflects state and local procurement of specific branded and generic medications for emergency medical services, public health programs, and multistate cooperative purchasing arrangements. Recent solicitations show purchasing departments and health agencies acquiring individual medication units—such as labetalol, epinephrine, adenosine, and diltiazem—through both direct supplier bids and cooperative purchasing frameworks that aggregate demand across multiple jurisdictions. State and local buyers include municipal fire rescue departments (Tampa Fire Rescue through the City of Tampa's Purchasing Department), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work involves supplying pharmaceuticals with strict expiration-date requirements, delivery timelines, quality assurance warranties, and compliance with FDA, OSHA, and cGMP standards, often with SLBE set-aside provisions and accessibility documentation requirements.

Recent activity spans Florida, Texas, and Minnesota. Representative opportunities include the City of Tampa's sealed-bid solicitation (26P00188) for Advanced Life Support Medications due April 8, 2026, with an estimated contract value of $40,000 and a one-year term plus renewal options; the Texas HHS Commission's Request for Information (HHS0017013, posted April 3, 2026) exploring direct-to-manufacturer prescription programs for its pharmacy benefit initiative; and MMCAP's Request for Proposal (S1070000015802, due March 26, 2026) establishing multistate contracts for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson. Vendors must demonstrate cGMP and DSCSA compliance, maintain relationships with authorized wholesalers, provide comprehensive insurance coverage, and accept performance-based pricing models and administrative fees.